Alfred Scheidegger

Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals.

Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany.

The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates.

ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future.

Palyon Medical Corp. develops medical devices for the treatment of chronic pain, spasticity and other neurological diseases. The company was founded by Greg David, David A. Present and Klaus G. Lederer on May 16, 2003 and is headquartered in Santa Clarita, CA.

Dottikon Exclusive Synthesis AG manufactures pharmaceutical ingredients. Its products and services exclusive synthesis, project management, performance chemicals, containment, quality management, recycling and waste treatment, and dottisol. The company was founded in 1913 and is headquartered in Dottikon, Switzerland.